Mounjaro injection 2.5mg/0.5ml prefilled pens
مونجارو حقن 2.5مجم/0.5مل اقلام معبأة للحقن
Tirazepatide
Unit price: 9435.00 EGP
Specifications
Uses & Indications
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated for chronic weight management in adults with obesity (BMI of 30 kg/m² or greater) or who are overweight (BMI of 27 kg/m² or greater) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).
How It Works
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates both GIP and GLP-1 receptors, leading to enhanced glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and increased satiety. These actions collectively contribute to improved glycemic control and reduction in body weight.
Dosage & Administration
injectable
Adults: For type 2 diabetes and chronic weight management: The initial dose is 2.5 mg injected subcutaneously once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. Doses can be increased in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum dose of 15 mg once weekly. The target maintenance doses for weight management are typically 10 mg or 15 mg once weekly.
Children: Not recommended. The safety and efficacy of tirzepatide have not been established in pediatric patients.
Side Effects
- Nausea (up to 44%)
- Diarrhea (up to 30%)
- Vomiting (up to 25%)
- Constipation (up to 17%)
- Abdominal pain (up to 15%)
- Dyspepsia
- Fatigue
Serious Side Effects
- Pancreatitis
- Severe gastrointestinal reactions
- Hypoglycemia (especially when used with insulin or sulfonylureas)
- Acute kidney injury
- Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema)
- Gallbladder disease (e.g., cholelithiasis, cholecystitis)
- Risk of thyroid C-cell tumors (observed in rodents, human relevance unknown)
Contraindications
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with known hypersensitivity to tirzepatide or any of its excipients.
Drug Interactions
Oral contraceptives: Tirzepatide may reduce the efficacy of oral contraceptives. Patients should be advised to use an additional barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. Drugs that slow gastric emptying (e.g., opioids, anticholinergics): May alter the absorption of concomitantly administered oral medications. Insulin and sulfonylureas: Increased risk of hypoglycemia; dose adjustments of insulin or sulfonylureas may be necessary.
Pregnancy & Lactation
Category: Not formally assigned (animal studies show reproductive toxicity)
There are limited data on tirzepatide use in pregnant women. Animal studies have shown reproductive toxicity. Tirzepatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is recommended to discontinue tirzepatide at least 1 month before a planned pregnancy.
Storage
Store tirzepatide in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If necessary, the pen can be stored at room temperature (below 30°C / 86°F) for up to 21 days. Protect from light.
Clinical Tips
Tirzepatide is administered once weekly, any time of day, with or without food. It should be injected subcutaneously into the abdomen, thigh, or upper arm. Patients should rotate injection sites with each dose. If a dose is missed, it should be administered as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, the missed dose should be skipped, and the next dose administered on the regularly scheduled day.
Frequently Asked Questions
What is tirzepatide used for?
Tirzepatide is used to improve blood sugar control in adults with type 2 diabetes and for chronic weight management in adults who are obese or overweight with at least one weight-related health condition.
How often do I take tirzepatide?
Tirzepatide is administered as a subcutaneous injection once weekly. Your doctor will determine the appropriate starting dose and how to gradually increase it.
What are the common side effects of tirzepatide?
Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. These are often mild to moderate and tend to decrease over time as your body adjusts to the medication.
Can tirzepatide be used for weight loss?
Yes, tirzepatide is approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related comorbidity, in conjunction with diet and exercise.
What should I do if I miss a dose of tirzepatide?
If you miss a dose, administer it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and take your next dose on your regularly scheduled day.
Similar — Tirazepatide
- Mounjaro injection 5mg/0.5ml prefilled pensEli lilly12250.00 EGP
- Mounjaro injection 7.5mg/0.5ml single dose prefilled pensEli lilly15455.00 EGP
- Mounjaro injection 12.5mg/0.5ml prefilled pensEli lilly18150.00 EGP
- Mounjaro injection 15mg/0.5ml prefilled pensEli lilly18150.00 EGP
- Mounjaro injection 10mg/0.5ml prefilled pensEli lilly15455.00 EGP
Medical Disclaimer
The information provided is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before starting or changing any medication.